Rene Gatsinga

Dr. Rene Gatsinga


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
RGRene Gatsinga
Rene Gatsinga
YTYu Guang Tan
Yu Guang Tan
WCWeiren Chen
Weiren Chen
XYXinyan Yang
Xinyan Yang
JTJeffrey Kit Loong Tuan
Jeffrey Kit Loong Tuan
JYJohn Shyi Peng Yuen
John Shyi Peng Yuen
Background: Various treatment regimens are now available for metastatic castrate-resistant prostate cancer (CRPC). This work evaluates the real-world prescription patterns of CRPC in a large tertiary care center and the factors influencing them. Methods: Health records of 330 patients with de novo metastatic hormone-sensitive prostate cancer (HSPC), treated and progressed to CRPC between 2016 and 2020, were reviewed from a prospective uro-oncological database. We studied their demographics, medical co-morbidities, treatment utilization patterns before and after progression to CRPC, and survival outcomes. Results: The median age was 74 years [interquartile range (IQR), 67–80 years] at diagnosis of CRPC. At CRPC, beyond androgen deprivation therapy (ADT) monotherapy, 70.3% (n=232) of patients received at least one additional line, 21.5% (n=71) received two lines, and 5.5% (n=18) received three lines of systemic treatments. As first-line treatment, novel hormonal agents (NHAs) were the most prescribed at 57.6% (n=190). The likelihood of receiving treatment was associated with age <65 years [odds ratio (OR) 2.08, P=0.01, 95% confidence interval (CI): 1.22–3.57] and lower Charlson Comorbidity Index (CCI) score (OR: 2.62, P=0.04, 95% CI: 1.07–6.45), treatment intensification for HSPC (OR 2.45, P=0.04, 95% CI: 1.07–5.62) and primary physician being an oncologist (OR 1.59, P=0.04, 95% CI: 1.04–2.48). Patients who received additional treatment lines at CRPC had longer survival (median: 23 vs. 17 months, OR 1.72, P<0.01, 95% CI: 1.23–2.38). Conclusions: More than one in four patients do not receive any additional treatment line beyond ADT monotherapy and have worse survival outcomes. Health status, prescribing physician, and treatment at HSPC appear to affect prescription patterns at the CRPC stage.

24 October 2024 in Medicina
Verified
Journal Article
Open access
PDF file
RGRene Gatsinga
Rene Gatsinga
BLBenjamin J. H. Lim
Benjamin J. H. Lim
NKNavin Kumar
Navin Kumar
JTJacinda Tan
Jacinda Tan
YLYouquan Li
Youquan Li
JYJohn Shyi Peng YUEN
John Shyi Peng YUEN
Background and Objectives: Radiation therapy (RT) plays a crucial role in managing prostate cancer, offering effective disease control and improving survival rates in both localized and recurrent cases. However, RT can lead to hemorrhagic cystitis, a significant late complication resulting in chronic morbidity and other health issues. This study aims to evaluate the real-world incidence of radiation-induced hemorrhagic cystitis requiring surgical intervention. Materials and Methods: This retrospective cohort study analyzed data from prostate cancer survivors treated for hematuria at our center between January 2014 and January 2024. Patients were included if cystoscopy identified radiation cystitis as the cause of hematuria. Descriptive statistics were used, and binomial logistic regression analyses with univariate and multivariate analysis were performed to identify risk factors for worse outcomes. Results: Fifty-two patients met the inclusion criteria. The estimated cumulative incidence at a median follow-up of 5.3 years was 4.5%. Among the participants, 21.2% required more than two transurethral bladder fulguration (TUBF) procedures, and 38.5% needed more than two hospital admissions for hematuria management. The median time to the first fulguration was 64 months. Blood transfusions were necessary in 53.8% of cases, and 38.5% required hyperbaric oxygen therapy. Ultimately, 5.8% of the patients underwent cystectomy. Univariate analysis identified ischemic heart disease (IHD) and antiplatelet therapy as significant risk factors (OR: 5.17 and 5.18, respectively), along with longer time to first fulguration (OR: 5.02). Multivariate analysis confirmed antiplatelet therapy (OR: 2.8, p = 0.05) and time to first TUBF (OR: 1.8, p = 0.02) as significant predictors of multiple procedures. Conclusions: Radiation cystitis remains a significant burden on prostate cancer survivors. Patients on antithrombotic agents, those with delayed initial presentations, and those who received radiation as salvage therapy are more likely to experience higher morbidity.

21 March 2022 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
RGRene Gatsinga
Rene Gatsinga
YTYu Guang Tan
Yu Guang Tan
NNNye Thane Ngo
Nye Thane Ngo
JTJonathan Sm Teo
Jonathan Sm Teo
We describe the case of a metastatic penile tumour of hepatocellular origin treated with surgical resection.